Finkelstein Thompson LLP Announces Investigation of Clinical Data, Inc.
22 Fevereiro 2011 - 6:43PM
Business Wire
Finkelstein Thompson LLP is investigating potential claims on
behalf of shareholders of Clinical Data, Inc. (“Clinical Data” or
the “Company”) (Nasdaq:CLDA) concerning the proposed acquisition of
the Company by Forest Laboratories, Inc (“Forest”). Under the terms
of the offer, Clinical Data shareholders will receive $30.00 in
cash per share owned and contingent consideration of up to $6.00
per share based up upon the achievement of certain commercial
milestones related to the Company’s antidepressant drug, Viibryd™.
The transaction is valued at approximately $1.2 billion.
The investigation is focused on the potential unfairness of the
consideration to Clinical Data shareholders, the process by which
the Board of Directors considered the transaction, and potential
conflicts of interests among Clinical Data Board members. In
particular, according to Yahoo! Finance, at least one analyst has
set a target price of $46.00 for Clinical Data shares.
If you are interested in discussing your rights as a Clinical
Data shareholder, or have information relating to this
investigation, please contact Finkelstein Thompson's Washington, DC
offices at (877) 337-1050 or by email at
contact@finkelsteinthompson.com.
Finkelstein Thompson LLP has spent over three decades delivering
outstanding representation to institutional and individual clients
in financial litigation, and has been appointed as lead or co-lead
counsel in dozens of shareholder class actions. Indeed, the firm
has served in leadership roles in cases that have recovered over $1
billion for investors and consumers.
To learn more about Finkelstein Thompson LLP, please visit our
web site at www.finkelsteinthompson.com. Attorney advertising.
Prior results do not guarantee similar outcomes.
Clinical Data (NASDAQ:CLDA)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Clinical Data (NASDAQ:CLDA)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Clinical Data, Inc. (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Finkelstein Thompson LLP